{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:36:19Z","timestamp":1777419379648,"version":"3.51.4"},"reference-count":30,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2008,4,22]],"date-time":"2008-04-22T00:00:00Z","timestamp":1208822400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2008,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Recombinant human coagulation factor VIIa (rVIIa) is a procoagulant indicated for treatment of bleeding in patients with hemophilia. A large proportion of rVIIa utilization is for off-label administration in nonhemophiliac patients with acute hemorrhage. Concerns of potentially inappropriate use, safety, and cost of rVIIa led to efforts to standardize use of this agent.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To comparatively describe the utilization of rVIIa upon implementation of an evidence-based guideline at a university hospital.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>With advisory direction from a multidisciplinary task force, an evidence-based guideline for use of rVIIa was developed, approved, and fully implemented. Assessment of appropriateness of use and retrospective review were required for all cases. Effects of these actions were evaluated by auditing and comparing rVIIa use in patients treated in two 6-month observation periods before and after guideline implementation. Outcomes assessed were proportions of patients deemed appropriate to receive rVIIa, compliance with dosing recommendations, and acquisition costs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Twenty-two and 29 patients were treated in the periods before and after guideline implementation, respectively. Patient characteristics were similar, except more cardiothoracic surgeries were performed in patients treated before implementation of the guideline. Indications for rVIIa use were judged appropriate in 21 (95.5%) before-cases and in all (100%) after-cases. The dose was compliant in 1 (4.6%) before-case and 27 (93.1%) after-cases (p conclusions: A guideline based on currently available evidence can serve to sustain the clinical appropriateness of rVIIa therapy and substantially decrease costs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1345\/aph.1l047","type":"journal-article","created":{"date-parts":[[2008,5,13]],"date-time":"2008-05-13T21:28:07Z","timestamp":1210714087000},"page":"771-776","source":"Crossref","is-referenced-by-count":6,"title":["Formulary Management of Recombinant Factor VIIa at an Academic Medical Center"],"prefix":"10.1177","volume":"42","author":[{"given":"Phillip S","family":"Owen","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice; Clinical Assistant Professor, College of Pharmacy and Health Sciences Center, Mercer University, Atlanta, GA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larry K","family":"Golightly","sequence":"additional","affiliation":[{"name":"Pharmacy CARE Team, University of Colorado Hospital"},{"name":"School of Pharmacy, University of Colorado\u2013Denver, Aurora, CO"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"MacLaren","sequence":"additional","affiliation":[{"name":"University of Colorado Hospital; Associate Professor, School of Pharmacy, University of Colorado\u2013Denver"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth A","family":"Ferretti","sequence":"additional","affiliation":[{"name":"Pharmacy Care Team, Pharmacy and Therapeutics Committee, University of Colorado Hospital, Aurora"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David B","family":"Badesch","sequence":"additional","affiliation":[{"name":"Pharmacy and Therapeutics Committee, University of Colorado Hospital; Professor of Pulmonary Sciences, School of Medicine, University of Colorado\u2013Denver"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2008,4,22]]},"reference":[{"key":"bibr1-aph.1L047","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.317.7153.273"},{"key":"bibr2-aph.1L047","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.312.7023.71"},{"key":"bibr3-aph.1L047","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200220150-00003"},{"key":"bibr4-aph.1L047","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2005.00045.x"},{"key":"bibr5-aph.1L047","doi-asserted-by":"publisher","DOI":"10.2165\/00063030-200013040-00007"},{"key":"bibr6-aph.1L047","unstructured":"Package insert. NovoSeven (recombinant factor VIIa). Princeton, NJ: NovoNordisk, October 2006."},{"key":"bibr7-aph.1L047","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-137-11-200212030-00009"},{"key":"bibr8-aph.1L047","doi-asserted-by":"publisher","DOI":"10.1097\/00001721-200307000-00007"},{"key":"bibr9-aph.1L047","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-3565(03)00295-7"},{"key":"bibr10-aph.1L047","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2005.10.008"},{"key":"bibr11-aph.1L047","doi-asserted-by":"publisher","DOI":"10.1097\/00001721-200104000-00005"},{"key":"bibr12-aph.1L047","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.34164"},{"key":"bibr13-aph.1L047","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200102150-00011"},{"key":"bibr14-aph.1L047","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-004-2181-0"},{"key":"bibr15-aph.1L047","doi-asserted-by":"publisher","DOI":"10.1186\/cc5132"},{"key":"bibr16-aph.1L047","doi-asserted-by":"publisher","DOI":"10.1097\/01.TA.0000171470.39742.8E"},{"key":"bibr17-aph.1L047","doi-asserted-by":"publisher","DOI":"10.1097\/00001721-200004001-00023"},{"key":"bibr18-aph.1L047","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-200502000-00006"},{"key":"bibr19-aph.1L047","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa042991"},{"key":"bibr20-aph.1L047","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.3.293"},{"key":"bibr21-aph.1L047","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.64.6.879"},{"key":"bibr22-aph.1L047","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000239154.51331.c4"},{"key":"bibr23-aph.1L047","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp060398"},{"key":"bibr24-aph.1L047","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp060093"},{"key":"bibr25-aph.1L047","unstructured":"MagnettiS, OinonenM, MatuszewskiK. An evaluation of off-label use of recombinant activated human factor VII (NovoSeven): patient characteristics, utilization trends, and outcomes of an electronic database of US academic health centers. P&T 2007;32:218-30."},{"key":"bibr26-aph.1L047","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2005.00548.x"},{"key":"bibr27-aph.1L047","unstructured":"NovoSeven\u2014MSN newsfeeds: legalview. htto:\/\/novoseven.legalview.com (accessed 2007 Dec 4)."},{"key":"bibr28-aph.1L047","unstructured":"RatkoTA, CummingsJP, MatuszewskiKA. Off-label use of recombinant activated factor VII (NovoSeven). P&T 2004;29:712-20."},{"key":"bibr29-aph.1L047","unstructured":"ShanderA, GoodnoughLT, RatkoTA. Consensus recommendations for the off-label use of recombinant human factor VIIa (NovoSeven) therapy. P&T 2005;30:644-58."},{"key":"bibr30-aph.1L047","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/53.16.1953"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1L047","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1L047","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:10:33Z","timestamp":1777374633000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.1L047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4,22]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["10.1345\/aph.1L047"],"URL":"https:\/\/doi.org\/10.1345\/aph.1l047","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,4,22]]}}}